AnalysesAs we wait for another NR it's interesting to note the Morningstar metrics. While the Fair Value sp has dipped a little to $.41 the 1-star price of overbought and overvalued territory is still strong at $.77. What's really notable is the 5-star price where THRM will be considered significantly undersold and undervalued. It's at $.22 ....uncharacteristically close to the current sp (for the majority of stocks).
This should mean that returning to a more substantial sp won't take much in the way of momentum. Even the resistance levels seemed to have converged with a range of $.255 to $.275. These will be easy to breach on news.
As some have intimated, it's now been two weeks since the end of device testing. There really should have been no obstacles to completing the final submission ....so it should be expected that the FDA review has already commenced.
Looking forward to the HALT and the subsequent NR indicating that Therma Bright has received an FDA EUA for AcuVid.
GLTE!!!